Arterial hypertension and cancer

被引:60
作者
Milan, Alberto [1 ]
Puglisi, Elisabetta [1 ]
Ferrari, Laura [2 ]
Bruno, Giulia [1 ]
Losano, Isabel [1 ]
Veglio, Franco [1 ]
机构
[1] Univ Turin, Dept Med Sci, Hypertens Unit, Turin, Italy
[2] Spedali Civil Brescia, Dept Med Oncol, I-25125 Brescia, Italy
关键词
arterial hypertension; cancer therapies; antihypertensive therapies; anti VEGF drugs; CALCIUM-CHANNEL BLOCKERS; ENDOTHELIAL GROWTH-FACTOR; CONVERTING-ENZYME-INHIBITORS; RENAL-CELL CARCINOMA; RANDOMIZED CONTROLLED-TRIALS; NF-KAPPA-B; BREAST-CANCER; BLOOD-PRESSURE; PANCREATIC-CANCER; BETA-BLOCKERS;
D O I
10.1002/ijc.28334
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Arterial hypertension and cancer are two of the most important causes of mortality in the world; correlations between these two clinical entities are complex and various. Cancer therapy using old (e.g., mitotic spindle poisons) as well as new (e.g., monoclonal antibody) drugs may cause arterial hypertension through different mechanisms; sometimes the increase of blood pressure levels may be responsible for chemotherapy withdrawal. Among newer cancer therapies, drugs interacting with the VEGF (vascular endothelial growth factors) pathways are the most frequently involved in hypertension development. However, many retrospective studies have suggested a relationship between antihypertensive treatment and risk of cancer, raising vast public concern. The purposes of this brief review have then been to analyse the role of chemotherapy in the pathogenesis of hypertension, to summarize the general rules of arterial hypertension management in this field and finally to evaluate the effects of antihypertensive therapy on cancer disease.
引用
收藏
页码:2269 / 2277
页数:9
相关论文
共 81 条
[1]   Calcium channel blockers and the risk of cancer:: A preclinical assessment [J].
Ahr, HJ ;
Bomhard, E ;
Enzmann, H ;
Karbe, E ;
Mager, H ;
Sander, E ;
Schlüter, G .
CARDIOVASCULAR DRUGS AND THERAPY, 1998, 12 (02) :157-169
[2]   Prevention of pancreatic cancer by the beta-blocker propranolol [J].
Al-Wadei, Hussein A. ;
Al-Wadei, Mohammed H. ;
Schuller, Hildegard M. .
ANTI-CANCER DRUGS, 2009, 20 (06) :477-482
[3]   Long-term use of antihypertensive drugs and risk of cancer [J].
Assimes, Themistocles L. ;
Elstein, Eleanor ;
Langleben, Adrian ;
Suissa, Samy .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 (11) :1039-1049
[4]   Home blood-pressure monitoring in patients receiving sunitinib [J].
Azizi, Michel ;
Chedid, Antoine ;
Oudard, Stephane .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (01) :95-97
[5]   Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324168 participants from randomised trials [J].
Bangalore, Sripal ;
Kumar, Sunil ;
Kjeldsen, Sverre E. ;
Makani, Harikrishna ;
Grossman, Ehud ;
Wetterslev, Jorn ;
Gupta, Ajay K. ;
Sever, Peter S. ;
Gluud, Christian ;
Messerli, Franz H. .
LANCET ONCOLOGY, 2011, 12 (01) :65-82
[6]   Beta Blockers and Breast Cancer Mortality: A Population-Based Study [J].
Barron, Thomas I. ;
Connolly, Roisin M. ;
Sharp, Linda ;
Bennett, Kathleen ;
Visvanathan, Kala .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (19) :2635-2644
[7]   VEGF ligands and receptors: implications in neurodevelopment and neurodegeneration [J].
Carmeliet, Peter ;
de Almodovar, Carmen Ruiz .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2013, 70 (10) :1763-1778
[8]   Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins [J].
Chae, Young Kwang ;
Valsecchi, Matias E. ;
Kim, Jongoh ;
Bianchi, Anabella Lucca ;
Khemasuwan, Danai ;
Desai, Ajit ;
Tester, William .
CANCER INVESTIGATION, 2011, 29 (09) :585-593
[9]   Emerging evidence for a functional angiotensin-converting - Enzyme 2-angiotensin-(1-7)-mas receptor axis more than regulation of blood pressure? [J].
Chappell, Mark C. .
HYPERTENSION, 2007, 50 (04) :596-599
[10]   Molecular Pathways: Beta-Adrenergic Signaling in Cancer [J].
Cole, Steven W. ;
Sood, Anil K. .
CLINICAL CANCER RESEARCH, 2012, 18 (05) :1201-1206